Trimebutine on the Development of Adverse Events Related to the Helicobacter Pylori Eradication Medications
NCT ID: NCT04403087
Last Updated: 2022-07-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
132 participants
INTERVENTIONAL
2021-05-01
2021-07-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effact of Helicobacter Hylori Eradication on the Development of Gastric Mucosa Pathology
NCT04029441
Effect of H. Pylori Eradication on The Improvement of Gastrointestinal Symptoms
NCT07272681
Effect of Oral Helicobacter Pylori Infection on the Efficacy of Gastroluminal Helicobacter Pylori Eradication Therapy
NCT05790525
Change of Gut Microbiome and Symptom After H.Pylori Eradication Therapy in Patients With Functional Dyspepsia
NCT04449185
The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study
NCT04030715
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The aim of this study was to evaluate the additive effect of trimebutine for the development of adverse events related to the H. pylori eradication regimen.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trimebutine add group
Addition of Trimebutine on the Bismuth-containing quadruple regimen
Trimebutine 100 MG
Trimebutine 100mg three times a day
Control group
Bismuth-containing quadruple regimen
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Trimebutine 100 MG
Trimebutine 100mg three times a day
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Subjects who underwent stomach resection
* Subjects less than 18 years of age
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chuncheon Sacred Heart Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chang Seok Bang
Associate professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Chang Seok Bang, MD, PHD
Role: PRINCIPAL_INVESTIGATOR
Hallym University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chuncheon Sacred Heart hospital
Chuncheon, Gangwon-do, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BCSHPAE
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.